We provide tailored, innovative solutions to help health and life sciences companies with their clinical development and commercialization journeys, maximizing patient access.
In 2022, Inizio was formed by bringing together the strengths and deep expertise of Ashfield, founded in 1999, and Huntsworth, established in 1983. With rich histories and decades of experience, the formation of Inizio united carefully acquired capabilities—purposefully designed to deliver exceptional value for our clients. Today, our global commercial services support clients through every pivotal moment of the asset lifecycle, from discovery to post-launch, with specialized expertise across all 14 therapeutic areas.
As you navigate the commercialization journey, you face various challenges along the way. Overcoming these challenges requires the support of a specialist partner who can help minimize friction and accelerate development at every pivotal moment. That’s where Inizio come in.
Across all stages of your journey to market, our cross-sector experts work closely with you to understand the complexities of your asset and propel it in the right direction – so that more people get the treatment they need, faster.
We support the full commercialization journey from early-stage development, through to loss of exclusivity, function by function, market by market, across all therapeutic areas.
We understand that every day is an opportunity to build towards the true value of your assets. Our biotech solutions are tailored and coordinated through a single strategic point of contact, ensuring a personalized approach to maximize the value of your innovations.
We enable the promotion of new technologies and support our clients in increasing patient engagement and adoption.
We support clients to target, communicate, and engage with consumers directly to achieve their strategic objectives.
We help our clients engage with patients and consumers in a complex and dynamic environment.
Inizio brings a world of possibilities to explore with our collective of industry experts. We are guided by our five commitments that allow our leaders to constantly grow and help us collectively build a stronger more successful business.
We empower everyone
We do the right thing
We work as one
We ask “what if?”
We rise to the challenge
Navigate this carousel with the arrows.
Paul is the CEO of Inizio, the largest provider of solutions that help health and life sciences companies bring new life saving medicines to market. Before this, Paul was appointed as CEO of Huntsworth plc in April 2015. He turned Huntsworth into a leading health care advisory business before taking the company private under CD&R. Prior to that, Paul enjoyed a 20-year career in London and New York with Hill & Knowlton Inc, the global communications consultancy and subsidiary of WPP plc, including nine years as its Chairman and CEO. Throughout this time, Paul advised many blue-chip and international clients across all geographies and sectors.
Previously COO at UDG Healthcare, and appointed as COO at Inizio in November 2021, Ryan provides strategic leadership across our global divisions by working with the executive management teams to establish and deliver long-term strategic growth plans. He has over 25 years’ experience in the pharmaceutical industry in commercial leadership roles. Prior to joining UDG Healthcare, Ryan was Regional Vice President Region South, Immunology and HCV lead for AbbVie Western Europe and Canada.
Ben was appointed Chief Financial Officer of Inizio following the acquisition of UDG Healthcare, having previously been CFO of Huntsworth Plc. Ben joined Huntsworth Plc in September 2016, stepping up to the Board in 2019. Before joining the team, he worked at ITE Plc, and International Exhibitions Organizer, as Group Financial Controller. Prior to that, Ben worked at Royal Bank of Scotland in banking roles, after training and qualifying with Deloitte in London. In his time at Inizio, Ben has overseen the transformation of the central functions to support the broader integration of the Group and to provide a platform for ongoing growth.
Grainne became part of the Inizio team after joining UDG Healthcare in June 2018 as the UDG Head of Finance, with responsibility for Group Finance, Ashfield Finance Functions, Global Procurement & Real Estate, and Finance Transformation. Since joining Inizio, Grainne has led the Finance Transformation projects across the group, partnering with IT to move all businesses to a common financial ERP system, and establishing Shared Services for 30+ Ashfield agencies. Prior to UDG, she worked as General Manager, Ireland, and Vice President, Finance with Alexion, a rare disease US biotech company, leading their expansion in Ireland and a €500 million investment in biologics and packaging facilities in Ireland. Grainne previously spent ten years working with Elan Pharmaceuticals in the United States and Ireland in various corporate, strategic and group finance roles.
Stephanie joined Inizio as the Global Chief Human Resources Officer (CHRO) in September 2022. She leads Inizio's global talent strategy and HR team, focusing on transforming the HR organization to deliver a best-in-class experience for our people and differentiating Inizio in the market as a global employer of choice. With over 25 years of international experience as a strategy and management consultant, corporate leader, Chief Human Resources Officer and Board member, Stephanie brings a wealth of global knowledge and expertise from across various industries including professional services, financial services, and engineering/construction.
Neil is an experienced Executive Director. He was the former CFO & COO of Huntsworth prior to the merger with UDG which formed Inizio. Before joining Huntsworth, Neil was CFO for several UK-listed public companies, having originally qualified as an accountant with PWC in the early 90’s. Neil has multiple responsibilities at Inizio. As Corporate Development Director, he heads M&A, leading on the Nucleus and Research Partnership transactions. He also leads property focusing on delivering the optimal property solution (space and environments) for employees, serves as the executive sponsor for both ESG and Diversity, Equity & Inclusion, helping to shape strategy and deliver a best-in-class positioning for the Company to ensure Inizio is as competitive as possible. He is also the Chairman of Accordience, Inizio’s non-healthcare PR agency Group.
Colin is Inizio’s Chief Commercial Officer and is responsible for our Commercial Activities and Business Development, with a particular emphasis on the support of our Large Enterprise Accounts and the infrastructure that supports our Global Sales Team. Prior to his current role, he was President of Inizio Advisory from September 2019, where he oversaw Inizio’s Consulting and Research Businesses. Before Inizio, Colin spent 20 years at ICON, where he held several leadership positions, including President of ICON Functional Services. Colin is a seasoned leader in the pharma industry, bringing 30 years of experience across both clinical development and commercialization. He has a strong track record of driving business growth, both organically and through M&A, and improving margins through process optimization.
Joining Medistrava in 2015, Elaine helped double the size of the organization through organic growth and acquisition to create a fully integrated medical, health economics and market access platform. Now, she joins us as President of Inizio Medical. As a trained neuropsychologist, Elaine has enjoyed a career in research and clinical practice before joining the industry, combining her background in science and behavior to drive evidence-based strategies that apply to real-world healthcare challenges.
As CEO & Founder of Evoke, Reid leads the organization globally. Reid founded Evoke in 2006 in pursuit of a simple yet powerful idea—to make health more human™. This idea caught fire with like-minded clients who were hungry for rich, insight-driven strategies that drive real change for brands and people.
Joining Ashfield in 2005 as a Regional Account Director in the UK, Greg Flynn has since worked with our teams across the UK, Japan and the US. He established and ran our joint venture in Japan before moving to the US in 2017 to lead Engage. Greg was previously the President of Engage from 2019 - 2025.
Using our connected suite of capabilities, we deliver expert guidance at each pivotal moment, maximizing asset potential and impact across therapeutic areas.